comparemela.com

Maribavir Would News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Takeda Pharmaceutical Company Limited: Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies

If Approved, Maribavir Would be the First and Only Inhibitor of CMV-specific UL97 Protein Kinase in the EU for Treatment of Adults with Post-transplant CMV Refractory (With or Without Resistance) to

United statesDaniel curranAbhi basuJun saitoErin marie bealsEuropean commissionDrug administrationInternational mediaExchange commissionEuropean unionTakeda pharmaceutical company limitedEuropean medicines agencyCommittee for medicinal products human useMaribavir wouldOnly inhibitorWithout resistance

vimarsana © 2020. All Rights Reserved.